Recent Updates
Recently added Catalysts
VYGR Positive Sentiment

Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program

Wednesday, December 6, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Voyager Therapeutics has announced the selection of a lead development candidate for its gene therapy program targeting SOD1 amyotrophic lateral sclerosis (ALS). The company plans to file an Investigational New Drug (IND) application by mid-2025, marking a significant step forward in their research efforts. This development highlights Voyager's commitment to advancing gene therapy in neurology.
Price reaction · baseline $7.44 (2023-12-05 close) · hit pre-market · clean, no other VYGR news in the window
day 0 close · peak
+2.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Voyager Therapeutics has selected a lead development candidate.
  • The candidate is part of a gene therapy program for SOD1 ALS.
  • IND filing is expected in mid-2025, indicating progress.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+14%
120-day peak, hindsight
Typical move
3%
average across 2 past catalysts
Cash runway
~17 mo
Low dilution risk
Lead asset
VP4896
Phase 3 · Alzheimer's Disease

Full Press Release Details

– IND filing expected in mid-2025 – LEXINGTON, Mass. , Dec. 06, 2023 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that it has selected a lead development candidate for its

Frequently Asked Questions

What candidate did Voyager Therapeutics select?

Voyager Therapeutics selected a lead development candidate for its SOD1 ALS gene therapy.

When is the IND filing expected?

The IND filing is expected in mid-2025.

What disease is the gene therapy targeting?

The gene therapy program targets SOD1 amyotrophic lateral sclerosis (ALS).

Where is Voyager Therapeutics located?

Voyager Therapeutics is based in Lexington, Massachusetts.

ShareAdd on Google
Tags: VYGR Viatris Investor Conferences Healthcare Voyager Therapeutics gene therapy SOD1 amyotrophic lateral sclerosis
Last updated: Dec 6, 2023

Biotech snapshot

Cash runway
$149M liquidity · $9M/mo burn
~17 mo
Low dilution risk
Lead asset
VP4896Phase 3
Alzheimer's Disease →

Catalyst track record

+14%
best trade around VYGR's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for VYGR.

See every catalyst's timing & PoA →